Enter drug's generic or brand name below. Results will appear here. Note: all drug related information obtained on this page is provided by RX List.
Using the RX LIST database:
(1) Enter the drug name in the search box below and hit ENTER
(2) The rx list web site will open here with the drug search completed. Next, scroll down the page to locate the link to the drug you are searching for and then click on the link.
INTRAROSA™
(prasterone) vaginal inserts
INTRAROSA (prasterone) vaginal insert is a vaginally administered steroid. Prasterone is identified chemically as 3β-hydroxyandrost-5-en-17-one. It has the empirical formula C19H28O2 with a molecular weight of 288.424 g/mol. Prasterone is a white to off-white crystalline powder insoluble in water and soluble in sodium lauryl sulfate (SLS). The structural formula is:
 |
Each INTRAROSA (prasterone) vaginal insert contains 6.5 mg of prasterone in 1.3 ml of off-white hard fat (Witepsol).
INTRAROSA™ is a steroid indicated for the treatment of moderate to severe dyspareunia, a symptom of vulvar and vaginal atrophy, due to menopause.
Administerone INTRAROSA vaginal insert once daily at bedtime, using the provided applicator.
Vaginal insert: 6.5 mgof prasterone, smooth, white to off-white solid fat bullet-shaped, measuring 28 mm in length, 9 mm in width at its wider end, and weighing 1.2 gram.
INTRAROSA is supplied as white to off-white 1.3 mL solid fat bullet-shaped, smooth vaginal inserts (containing 6.5 mg of prasterone). INTRAROSA is available in small boxes of 4 blister packs containing 7 vaginal inserts (28 vaginal inserts per box). The small box (containing the vaginal inserts) is supplied inside a larger box containing 28 applicators (NDC 64011-601-28).
Store at 41°F to 86°F (5°C to 30°C). Can be stored at room temperature or in the refrigerator.
Manufactured for: Endoceutics, Inc. Quebec City, Canada, G1V 4M7. Distributed by: AMAG Pharmaceuticals, Inc. Waltham, MA 02451. Revised: Feb 2018
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
In four (4) placebo-controlled, 12-week clinical trials [91% -White Caucasian non-Hispanic women, 7% -Black or African American women, and 2% -“Other” women, average age 58.8 years of age (range 40 to 80 years of age)], vaginal discharge is the most frequently reported treatment-emergent adverse reaction in the INTRAROSA treatment group with an incidence of ≥ 2 percent and greater than reported in the placebo treatment group. There were 38 cases in 665 participating postmenopausal women (5.71 percent) in the INTRAROSA treatment group compared to 17 cases in 464 participating postmenopausal women (3.66 percent) in the placebo treatment group.
In a 52-week non-comparative clinical trial [92% -White Caucasian non-Hispanic women, 6% Black or African American women, and 2% -“Other” women, average age 57.9 years of age (range 43 to 75 years of age)], vaginal discharge and abnormal Pap smear at 52 weeks were the most frequently reported treatment-emergent adverse reaction in women receiving INTRAROSA with an incidence of ≥ 2 percent. There were 74 cases of vaginal discharge (14.2 percent) and 11 cases of abnormal Pap smear (2.1 percent) in 521 participating postmenopausal women. The eleven (11) cases of abnormal Pap smear at 52 weeks include one (1) case of low-grade squamous intraepithelial lesion (LSIL), and ten (10) cases of atypical cells of undetermined significance (ASCUS).
No Information provided
Included as part of the PRECAUTIONS section.
Estrogen is a metabolite of prasterone. Use of exogenous estrogen is contraindicated in women with a known or suspected history of breast cancer. INTRAROSA has not been studied in women with a history of breast cancer.
Advise the patient to read FDA-approved patient labeling (Patient Information and Instructions for Use).
Inform postmenopausal women that vaginal discharge may occur with INTRAROSA[see ADVERSE REACTIONS].
Inform postmenopausal women that abnormal Pap smear findings may occur with INTRAROSA [see ADVERSE REACTIONS].
Long-term studies in animals to evaluate carcinogenic potential have not been conducted with prasterone.Two metabolites of prasterone, testosterone and estradiol, are carcinogenic in animals.
Prasterone was not genotoxic in the in vitro bacterial mutagenesis assay (Ames test), the in vitro chromosomal aberrations assay with human peripheral blood lymphocytes, and in vivo in the mouse bone marrow micronucleus assay.
Fertility studies were not conducted with prasterone.
INTRAROSA is indicated only in postmenopausal women.There are no data with INTRAROSA use in pregnant women regarding any drug-associated risks. Animal reproduction studies have not been conducted with prasterone.
INTRAROSA is indicated only in postmenopausal women.There is no information on the presence of prasterone in human milk, the effects on the breastfed infant, or the effects on milk production.
Safety and effectiveness have not been established in pediatric patients.
Of the 1522 prasterone-treated postmenopausal women enrolled in the four placebo-controlled 12-week and one open-label 52-week clinical trial, 19and 11 percent, respectively, were 65 years of age or older.
The effect of renal impairment on the pharmacokinetics of prasterone has not been studied.
The effect of hepatic impairment on the pharmacokinetics of prasterone has not been studied.
No Information provided
Undiagnosed abnormal genital bleeding: Any postmenopausal woman with undiagnosed, persistent or recurring genital bleeding should be evaluated to determine the cause of the bleeding before consideration of treatment with INTRAROSA.
Prasterone is an inactive endogenous steroid and is converted into active androgens and/or estrogens.The mechanism of action of INTRAROSA in postmenopausal women with vulvar and vaginal atrophy is not fully established.
In a study conducted in postmenopausal women, administration of the INTRAROSA vaginal insert once daily for 7 days resulted in a mean prasterone Cmax and area under the curve from 0 to 24 hours (AUC0-24) at Day 7 of 4.4 ng/mL and 56.2 ng•h/mL, respectively, which were significantly higher than those in the group treated with placebo (Table 1). The Cmax and AUC0-24 of the metabolites testosterone and estradiol were also slightly higher in women treated with the INTRAROSA vaginal insert compared to those receiving placebo.
Table 1. Cmax and AUC0-24 of Prasterone, Testosterone,
and Estradiol on Day 7 Following Daily Administration of Placebo or INTRAROSA
(mean ± S.D).
| Placebo (N=9) | INTRAROSA (N=10) | ||
| Prasterone | Cmax(ng/mL) | 1.60 (±0.95) | 4.42 (±1.49) |
| AUC0-24 (ng•h/mL) | 24.82 (±14.31) | 56.17 (±28.27) | |
| Testosterone | Cmax(ng/mL) | 0.12 (±0.04)1 | 0.15 (±0.05) |
| AUC0-24 (ng•h/mL) | 2.58 (±0.94)1 | 2.79 (±0.94) | |
| Estradiol | Cmax(pg/mL) | 3.33 (±1.31) | 5.04 (±2.68) |
| AUC0-24 (pg•h/mL) | 66.49 (±20.70) | 96.93 (±52.06) | |
| 1 : N=8 | |||
Figure 1: Serum Concentrations of Prasterone (A), Testosterone (B), and Estradiol (C) Measured Over a 24h
Period on Day 7Following Daily Administration of Placebo or INTRAROSA (mean ± S.D.).
 |
In two primary efficacy trials, daily administration of INTRAROSA vaginal insert for 12 weeks increased mean serum Ctrough of prasterone and its metabolites testosterone and estradiol by 47%, 21% and 19% from baseline, respectively. This comparison based on Ctrough may underestimate the magnitude of increase in prasterone and metabolites’ exposure because it does not take into account the overall concentration-time profile following administration of INTRAROSA.
Metabolism
Exogenous prasterone is metabolized in the same manner as endogenous prasterone. Human steroidogenic enzymes such as hydroxysteroid dehydrogenases, 5α-reductases and aromatases transform prasterone into androgens and estrogens.
The effectivenessof INTRAROSA on moderate to severe dyspareunia, a symptom of vulvar and vaginal atrophy, due to menopause was examined in twoprimary12-week placebo-controlled efficacy trials.
The first clinical trial (Trial 1) was a 12-week randomized, double-blind and placebocontrolledtrial that enrolled 255 generally healthy postmenopausal women between 40 to 75 years of age (mean 58.6 years) who, at baseline, identified moderate to severe dyspareunia as their most bothersome symptom of vulvar and vaginal atrophy. In addition to moderate to severe dyspareunia, women had ≤ 5% superficial cells on vaginal smear and a vaginal pH > 5.Women were randomized in a 1:1:1 ratio between three treatment groups who received daily INTRAROSA(n=87),one active comparator vaginal insert (n=87), or placebo (n=81). All women were assessed for improvement from Baseline to Week 12 for fourco-primary efficacy endpoints: most bothersome moderate to severe symptom of dyspareunia, the percentage of vaginal superficial cells, the percentage of parabasal cells, and vaginal pH.
The second clinical trial (Trial 2) was a 12-week randomized, double-blind and placebocontrolledtrial that enrolled 558 generally healthy postmenopausal women between 40 to 80 years of age (mean 59.5 years) who, at baseline, had identified moderate to severe dyspareunia as their most bothersome symptom of vulvar and vaginal atrophy. In addition to dyspareunia, women had ≤ 5% superficial cells on vaginal smear and a vaginal pH > 5. Women were randomized in a 2:1 ratio to receive once daily vaginal insert containing 6.5 mg INTRAROSA (n=376) or placebo (n=182). The primary endpoints and study conduct were the same or similar to those in Trial 1.
The primary efficacy results obtained in the Intent-to-Treat (ITT) population in Trial 1 are shown in Table 2.
Table 2: Efficacy Summary in Primary 12-Week Trial 1:
ITT Population (LOCF)
| Placebo N = 77 |
INTRAROSA N = 81 |
|
| Dyspareunia | ||
| Baseline Mean Severity | 2.58 | 2.63 |
| Week 12 Mean Severity | 1.71 | 1.36 |
| Mean Change in Severity(SD) | -0.87 (0.95) | -1.27 (0.99) |
| Difference from Placebo1 | - | -0.40 |
| p-value2 | - | 0.0132 |
| % Superficial Cells | ||
| Baseline Mean | 0.73 | 0.68 |
| Week 12 Mean | 1.64 | 6.30 |
| Mean Change (SD) | 0.91 (2.69) | 5.62 (5.49) |
| Difference from Placebo1 | - | 4.71 |
| p-value2 | - | <0.0001 |
| % Parabasal Cells | ||
| Baseline Mean | 68.48 | 65.05 |
| Week 12 Mean | 66.86 | 17.65 |
| Mean Change (SD) | -1.62 (28.22) | -47.40 (42.50) |
| Difference from Placebo1 | - | -45.77 |
| p-value2 | - | <0.0001 |
| Vaginal pH | ||
| Baseline Mean | 6.51 | 6.47 |
| Week 12 Mean | 6.31 | 5.43 |
| Mean Change (SD) | -0.21 (0.69) | -1.04 (1.00) |
| Difference from Placebo1 | - | -0.83 |
| p-value2 | - | <0.0001 |
| 1Difference from placebo =INTRAROSA (Week 12
mean – Baseline mean) – Placebo (Week 12 mean – Baseline mean). 2ANCOVA: Treatment as the main factor and Baseline value as the covariate. |
||
The primary efficacy results obtained in the Intent-to-Treat (ITT) population in Trial 2 are shown in Table 3.
Table 3: Efficacy Summary in
Primary 12-Week Trial 2: ITT Population (LOCF)
| Placebo N = 157 |
INTRAROSA N = 325 |
|
| Dyspareunia | ||
| Baseline Mean Severity | 2.56 | 2.54 |
| Week 12 Mean Severity | 1.50 | 1.13 |
| Mean Change in Severity (SD) | -1.06 (1.02) | -1.42 (1.00) |
| Difference from Placebo1 | - | -0.35 |
| p-value2 | - | 0.0002 |
| % Superficial Cells | ||
| Baseline Mean | 1.04 | 1.02 |
| Week 12 Mean | 2.78 | 11.22 |
| Mean Change (SD) | 1.75 (3.33) | 10.20(10.35) |
| Difference from Placebo1 | - | 8.46 |
| p-value2 | - | <0.0001 |
| % Parabasal Cells | ||
| Baseline Mean | 51.66 | 54.25 |
| Week 12 Mean | 39.68 | 12.74 |
| Mean Change (SD) | -11.98 (29.58) | -41.51 (36.26) |
| Difference from Placebo1 | - | -29.53 |
| p-value2 | - | <0.0001 |
| Vaginal pH | ||
| Baseline Mean | 6.32 | 6.34 |
| Week 12 Mean | 6.05 | 5.39 |
| Mean Change (SD) | -0.27 (0.74) | -0.94 (0.94) |
| Difference from Placebo1 | - | -0.67 |
| p-value2 | - | <0.0001 |
| 1Difference from placebo =INTRAROSA (Week 12
mean – Baseline mean) – Placebo (Week 12 mean – Baseline mean). 2ANCOVA: Treatment as the main factor and Baseline value as the covariate. |
||
INTRAROSA™
(in trah ROE sah)
(prasterone) vaginal inserts
What is INTRAROSA vaginal inserts?
INTRAROSA vaginal inserts are a prescription medicine used in women after menopause to treat moderate to severe pain during sexual intercourse caused by changes in and around the vagina that happen with menopause. It is not known if INTRAROSA vaginal inserts are safe and effective in children.
Do not use INTRAROSA vaginal inserts if you have vaginal bleeding that has not been checked by your healthcare provider.
Before using INTRAROSA vaginal inserts, tell your healthcare provider about all of your medical conditions, including if you:
Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.
How should I use INTRAROSA vaginal inserts?
What are the possible side effects of INTRAROSA vaginal inserts?
The most common side effects of INTRAROSA vaginal inserts are vaginal discharge and changes on Pap smear.
These are not all of the possible side effects of INTRAROSA vaginal inserts.
Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
How should I store INTRAROSA vaginal inserts?
Keep INTRAROSA vaginal inserts and all medicines out of the reach of children.
General Information about the safe and effective use of INTRAROSA vaginal inserts.
Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. Do not use INTRAROSA vaginal inserts for a condition for which it was not prescribed. Do not give INTRAROSA vaginal inserts to other people, even if they have the same symptoms that you have. It may harm them. You can ask your pharmacist or healthcare provider for information about INTRAROSA vaginal inserts that is written for health professionals.
What are the ingredients in INTRAROSA vaginal inserts?
Active ingredient: prasterone
Inactive ingredient: off-white hard fat (Witepsol)
For more information, go to www.intrarosa.com or call 1-877-411-2510.
Instructions for Use
INTRAROSA
(in trah ROE sah) (prasterone) vaginal inserts
How should I use INTRAROSA vaginal inserts?
STEP 1
1a. Remove 1 applicator from the package.
1b. Pull back on the plunger until it stops to activate the applicator. The applicator must be activated before use. Place the applicator on a clean surface.
 |
STEP 2
Slowly pull the plastic tabs on the vaginal insert away from each other while keeping the vaginal insert still between your fingers. Carefully remove the vaginal insert from the plastic wrap. If a vaginal insert falls on an unsanitary surface, replace it with a new one.
 |
STEP 3
Place the flat end of the vaginal insert into the open end of the activated applicator as shown. You are now ready to insert the vaginal insert into your vagina.
 |
STEP 4
Hold the applicator between your thumb and middle finger. Leave your index (pointer) finger free to press the applicator plunger after the applicator is inserted into your vagina.
 |
STEP 5
Select the position for insertion of the vaginal insert that is most comfortable for you.
5a. Lying position
 |
5b. Standing position
 |
STEP 6
Gently slide the vaginal insert end of the applicator into your vagina as far as it will comfortably go.
Do not use force.
 |
STEP 7
Press the applicator plunger with your index (pointer) finger to release the vaginal insert. Remove the applicator and throw it away after use.
 |
For more information, go to www.intrarosa.com or call 1-877-411-2510.
This Patient Information and Instructions for Use have been approved by the U.S. Food and Drug Administration.
